Current Molecular Advancements in Chimeric Antigen Receptor (CAR-T) Cells for the Treatment of Leukemia.

J Adolesc Young Adult Oncol

Department of Pediatric Oncology, Hematology and Trasnplantology, Poznan University of Medical Sciences, Poznan, Poland.

Published: August 2022

Chimeric antigen receptor T (CAR-T) is a relatively new treatment for pediatric leukemia and has been the focus of recent advancements. CAR is manufactured to express T cells through various ways such as using retroviruses, transposons and transposase, electroporation, and CRISPR (clustered regularly interspaced short palindromic repeats). Together, it provides flexibility since it recognizes proteins without the need of antigen processing and presentation, can recognize carbohydrates and lipids, and it has been proven to be cost-effective. Despite these benefits however, problems faced by this therapy include unrecognized tumor proteins possibly escaping the system, CAR T cell expression being transient, and the therapy being one of the most expensive cancer drug ever approved. As a result, recent progress has been ongoing where researchers have combined CAR-T cells with natural killer (NK) cells and different cytokines to maximize its efficacy and potency while limiting potential risks such as cytokine release syndrome. Consequently, these cells gained the ability to be universal-being able to be used to treat multiple patients, maintain viability for a longer period, and prevent relapse.

Download full-text PDF

Source
http://dx.doi.org/10.1089/jayao.2021.0102DOI Listing

Publication Analysis

Top Keywords

chimeric antigen
8
antigen receptor
8
receptor car-t
8
car-t cells
8
cells
5
current molecular
4
molecular advancements
4
advancements chimeric
4
cells treatment
4
treatment leukemia
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!